Bibliography
- Langlois JA, Rutland-brown W, Thomas KE. Traumatic brain injury in the United States: Emergency department visits, hospitalizations, and deaths. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2006
- Roberts I, Yates D, Sandercock P, et al. Crash trail collaborators. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004;364:1321-8
- Rosner MJ, Rosner SD, Johnson AH. Cerebral perfusion pressure: Management protocol and clinical results. Journal of Neurosurgery 1995;83:949-62
- Bruns J Jr, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia 2003;44(Supp 10):2-10
- Marik PE, Varon J, Trask T. Management of head trauma. Chest 2002;122:699-711
- Jones PA, Andrews PJ, Midgley S, et al. Measuring the burden of secondary insults in head-injured patients during intensive care. J Neurosurg Anesthesiol 1994;6(1):4-14
- Fearnside MR, Cook RJ, Mcdougall P, et al. The Westmead Head Injury Project outcome in severe head injury. A comparative analysis of pre-hospital, clinical and CT variables. Br J Neurosurg 1993;7(3):267-79
- Brain Trauma Foundation. Management of severe traumatic brain injury. Journal of Neurotrauma 2007;24:S1-S95
- Hatton J. Pharmacological treatment of traumatic brain injury. CNS Drugs 2001;15(7):553-81
- Singleton RH, Stone JR, Okonkwo DO, et al. The immunophilin ligand FK506 attenuates axonal injury in an impact-acceleration model of traumatic brain injury. J Neurotrauma 2001;18(6):607-14
- Barten MJ, Tarnok A, Garbade J, et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 2007;40:50-63
- Okonkwo DO, Buki A, Siman R, et al. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. Neuroreport 1999;10:353-8
- Marmarou CR, Povlishock JT. Administration of the immunophilin ligand FK506 differentially attenuates neurofilament compaction and impaired axonal transport in injured axons following diffuse traumatic brain injury. Exp Neurol 2006;197:353-62
- Scheff SW, Sullivan PG. Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents. J Neurotrauma 1999;16:783-92
- Lozier AP, Sciacca RR, Romagnoli MF, et al. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery 2002;51:170-82
- Boddie DE, Currie DG, Eremin O, et al. Immune suppression and isolated severe head injury: a significant clinical problem. Br J Neurosurg 2003;17(5):405-17
- Quattrocchi KB, Frank EH, Miller CH, et al. Severe head injury: effect upon cellular immune function. Neurol Res 1991;13(1):13-20
- Quattrocchi KB, Frank EH, Miller CH, et al. Impairment of helper T-cell function and lymphokine-activated killer cytotoxicity following severe head injury. J Neurosurg 1991;75(5):766-73
- Hatton J, Rosbolt B, Empey P, et al. Dosing and safety of cyclosporine in patients with severe brain injury. J Neurosurg 2008;109:699-707
- Young AB, Ott LG, Thompson JS, et al. The cellular immune depression of nonsteroid treated severely head-injured patients [abstract]. Southern Neurosurgical Society. Scottsdale, AZ: Neurosurgery 1985;722-3
- Package insert. Cyclosporine (Sandimmune). East Hanover, NJ: Novartis Pharmaceuticals Corporation March 2007
- Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323(8):497-502
- Rezzani R. Cyclosporine A and adverse effects on organs: histochemical studies. Prog Histochem Cytochem 2004;39:85-128
- Magnasco A, Rossi A, Catarsi P, et al. Cyclosporin and organ specific toxicity: Clinical aspects, pharmacogenetics, and perspectives. Current Clinical Pharmacology 2008;3:166-73
- Maas AI, Murray G, Henney III H, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurology 2006;5:38-45
- Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial. Crit Care Med 2002;30(3):548-54
- Boucher BA, Hanes SD. Pharmacokinetic alterations after severe head injury. Clinical Pharmacokinetics 1998;35(3):209-21
- Sullivan PG, Rabchevsky AG, Hicks RR, et al. Dose-response curve and optimal dosing regimen of cyclosporin A after traumatic brain injury in rats. Neuroscience 2000;101(2):289-95
- Lee G, Dallas S, Hong M, et al. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacological Reviews 2001;53(4):569-96
- Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nature Reviews Neuroscience 2005;6(8):591-602
- Empey PE, Mcnamara PJ, Young B, et al. Cyclosporin A disposition following acute traumatic brain injury. J Neurotrauma 2006;23(1):109-16
- Mckindley DS, Boucher BA, Hess MM, et al. Effect of acute phase response on phenytoin metabolism in neurotrauma patients. J Clin Pharmacol 1997;37(2):129-39
- Yee GC, Salomon DR. Cyclosporine. In: Evans WE, Schentag JJ, Jusko WJ, editors, Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd edition. Baltimore, MD: Lippincott Williams & Wilkins; 1992;28:1-40
- Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg 1999;91:593-600
- Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: A focus on hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med 2007;35(9):2196-204
- Keown PA. Molecular and clinical therapeutics of cyclosporine in transplantation. In: Ginns LC, Cosimi AB, Morris PJ, editors, Transplantation. 1 edition. Malden, MA: Blackwell Science, Inc 1999;101-3
- Sullivan PG, Rabchevsky AG, Waldmeier PC, et al. Mitochondrial permeability transition in CNS trauma: Cause or effect of neuronal cell death? J Neurosci Res 2005;79:231-9
- Kovarik JM, Koelle EU. Cyclosporin pharmacokinetics in the elderly. Drugs Aging 1999;15(3):197-205
- Baraldo M, Ferraccioli G, Pea F, et al. Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy. Pharmacol Res 1999;40(6):483-6
- Ptachcinski RJ, Venkataramanan R, Rosenthal JT, et al. Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther 1985;38:296-300